Clinical Trial Update: A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease [Phase 4]

View source ↗

Summary

A Phase 4 open-label study assessing caregiver preference, safety, and tolerability of the rivastigmine transdermal patch (Exelon Patch) in Alzheimer's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED